Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
49.54
-0.11 (-0.22%)
At close: Apr 28, 2026, 4:00 PM EDT
49.39
-0.16 (-0.31%)
After-hours: Apr 28, 2026, 7:42 PM EDT
Company Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.
The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc
| Country | United States |
| Founded | 1996 |
| IPO Date | Jun 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Pablo Legorreta |
Contact Details
Address: 110 East 59th Street New York, New York 10022 United States | |
| Phone | 212 883 0200 |
| Website | royaltypharma.com |
Stock Details
| Ticker Symbol | RPRX |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $28.00 |
| CIK Code | 0001802768 |
| CUSIP Number | G7709Q104 |
| ISIN Number | GB00BMVP7Y09 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Pablo Legorreta | Founder, Chairman of the Board and Chief Executive Officer |
| Terrance P. Coyne | Executive Vice President and Chief Financial Officer |
| Christopher Hite | Chairman of Partnering and Investments |
| Dr. Marshall Jonathan Urist M.D., Ph.D. | Executive Vice President of Research and Investments |
| Ashwin Pai M.D. | Executive Vice President of Investments and Partnering |
| Eric Cornelius Schneider | Senior Vice President and Chief Technology Officer |
| Dr. James Folmar Reddoch Ph.D. | Executive Vice President of Investments and Chief Scientific Officer |
| Arthur Richard McGivern J.D. | Executive Vice President and Chief Legal Officer |
| Molly Sawaya | Executive Vice President and Head of Human Capital |
| Sandy Balkin Ph.D. | Senior Vice President of Strategy and Analytics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | 144 | Filing |
| Apr 13, 2026 | 8-K | Current Report |
| Apr 10, 2026 | ARS | Filing |
| Apr 10, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2026 | 144 | Filing |
| Apr 1, 2026 | 13F-NT | Filing |
| Mar 23, 2026 | 144 | Filing |
| Mar 19, 2026 | 144 | Filing |
| Mar 18, 2026 | 144 | Filing |